Viera Illíková

Viera Illíková

Auto-generated profile, based on publicly available information

Viera Illíková

Department of Arrhythmias and Cardiac Pacing Paediatric Cardiac Centre, National Institute of Cardiovascular Diseases in Bratislava Bratislava Slovakia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2020 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
MBMarko Bjeloševič
Marko Bjeloševič
VIViera Illíková
Viera Illíková
JTJaroslav Tomko
Jaroslav Tomko
POPeter Olejník
Peter Olejník
MCMichal Chalupka
Michal Chalupka
RHRobert HATALA
Robert HATALA

8 March 2026 in Journal of Arrhythmia
Verified
Journal Article
Open access
MBMarko Bjeloševič
Marko Bjeloševič
POPeter Olejník
Peter Olejník
JTJaroslav Tomko
Jaroslav Tomko
MCMichal Chalupka
Michal Chalupka
VIViera Illíková
Viera Illíková
Aims: Implantable cardioverter‐defibrillator (ICD) therapy in children, particularly for primary prevention, remains under investigation, with limited data from less affluent European countries. With increasing use of fully subcutaneous (S‐ICD) and extravascular (EV‐ICD) systems, we analyzed epidemiology, indications, complications, and outcomes in pediatric ICD recipients at our tertiary center. Methods: This retrospective, population‐based, nationwide, single‐center study consecutively analyzed medical records from 2012 to 2025. Patients aged 0–18 years who underwent ICD implantation were included. Kaplan–Meier analyses were performed for shock‐free and mortality endpoints. Results: Forty‐nine patients were included, corresponding to an estimated national incidence of approximately one ICD implantation per 22 000 live births. ICDs were predominantly implanted for secondary prevention (80%). Long QT syndrome (32%) and hypertrophic cardiomyopathy (22%) were the most frequent diagnoses. During 207 patient‐years of follow‐up (median follow‐up 4 years), appropriate ICD shocks occurred in 27% of patients exclusively in the secondary prevention group. No appropriate therapies occurred in the primary prevention group despite higher overall mortality. Inappropriate shocks occurred in 22% of patients. Device‐related major complications affected 17% of implanted systems. Median transvenous ICD battery longevity was 6.5 years. Overall mortality was 6%, all related to underlying structural heart disease, with no ICD‐related deaths. S‐ICDs demonstrated a favorable acute and mid‐term safety profile in patients without pacing requirements. Conclusions: Pediatric ICD therapy is limited by substantial device‐related morbidity and imperfect risk stratification for primary prevention. The emerging S‐ICD and EV‐ICD systems represent promising, less invasive alternatives for selected pediatric patients.